Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARCT POWR Grades
- Growth is the dimension where ARCT ranks best; there it ranks ahead of 76.05% of US stocks.
- The strongest trend for ARCT is in Growth, which has been heading up over the past 179 days.
- ARCT's current lowest rank is in the Stability metric (where it is better than 4.12% of US stocks).
ARCT Stock Summary
- Of note is the ratio of Arcturus Therapeutics Holdings Inc's sales and general administrative expense to its total operating expenses; merely 7.47% of US stocks have a lower such ratio.
- ARCT's price/sales ratio is 61.99; that's higher than the P/S ratio of 96.64% of US stocks.
- With a year-over-year growth in debt of 278.34%, Arcturus Therapeutics Holdings Inc's debt growth rate surpasses 95.72% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Arcturus Therapeutics Holdings Inc are RNA, ANAB, RAPT, ATRA, and FGEN.
- ARCT's SEC filings can be seen here. And to visit Arcturus Therapeutics Holdings Inc's official web site, go to www.arcturusrx.com.
ARCT Valuation Summary
- In comparison to the median Healthcare stock, ARCT's price/earnings ratio is 124.38% lower, now standing at -8.9.
- Over the past 96 months, ARCT's price/sales ratio has gone NA NA.
- ARCT's EV/EBIT ratio has moved up 141.8 over the prior 96 months.
Below are key valuation metrics over time for ARCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ARCT | 2021-08-31 | 165.9 | 4.7 | -8.9 | -6.6 |
| ARCT | 2021-08-30 | 162.4 | 4.6 | -8.7 | -6.4 |
| ARCT | 2021-08-27 | 171.6 | 4.9 | -9.2 | -6.9 |
| ARCT | 2021-08-26 | 165.6 | 4.7 | -8.8 | -6.6 |
| ARCT | 2021-08-25 | 161.2 | 4.6 | -8.6 | -6.4 |
| ARCT | 2021-08-24 | 155.1 | 4.4 | -8.3 | -6.0 |
ARCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ARCT has a Quality Grade of D, ranking ahead of 24% of graded US stocks.
- ARCT's asset turnover comes in at 0.02 -- ranking 368th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ARCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.020 | 1 | -32.552 |
| 2021-03-31 | 0.025 | 1 | -19.685 |
| 2020-12-31 | 0.037 | 1 | -30.242 |
| 2020-09-30 | 0.066 | 1 | -5.591 |
| 2020-06-30 | 0.115 | 1 | -4.145 |
| 2020-03-31 | 0.244 | 1 | -2.814 |
ARCT Price Target
For more insight on analysts targets of ARCT, see our ARCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $78.46 | Average Broker Recommendation | 1.88 (Hold) |
ARCT Stock Price Chart Interactive Chart >
ARCT Price/Volume Stats
| Current price | $16.16 | 52-week high | $65.00 |
| Prev. close | $15.74 | 52-week low | $11.70 |
| Day low | $15.23 | Volume | 683,400 |
| Day high | $16.56 | Avg. volume | 639,336 |
| 50-day MA | $17.51 | Dividend yield | N/A |
| 200-day MA | $29.92 | Market Cap | 426.93M |
Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio
Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.
Latest ARCT News From Around the Web
Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue EstimatesAlimera Sciences (ALIM) delivered earnings and revenue surprises of -55.26% and 0.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out forArcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, February 19, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022SAN DIEGO, February 16, 2022--Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022 |
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceSAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference |
ARCT Price Returns
| 1-mo | -19.12% |
| 3-mo | -48.16% |
| 6-mo | -57.98% |
| 1-year | -53.47% |
| 3-year | 73.02% |
| 5-year | 104.30% |
| YTD | -56.34% |
| 2021 | -14.68% |
| 2020 | 299.08% |
| 2019 | 139.96% |
| 2018 | -43.02% |
| 2017 | -45.92% |
Loading social stream, please wait...